NewEdge Advisors’s Ascendis Pharma A/S ASND Stock Holding History

NewEdge Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.47K	Sell	13 -30	-70%	-$7.01K	﹤0.01%	3816
2026 Q1	$9.84K	Sell	43 -47	-52%	-$10.5K	﹤0.01%	3406
2025 Q4	$19.2K	Buy	+90	New	+$18.6K	﹤0.01%	3275

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

NewEdge Advisors's ASND Position: Q2 2026 in Review

NewEdge Advisors reduced its Ascendis Pharma A/S (ASND) stake by 70% in Q2 2026, selling an estimated $7.01K and leaving 13 shares worth $3.47K. The position accounts for ﹤0.01% of the portfolio, ranked #3816.

NewEdge Advisors first reported a position in ASND in Q4 2025 and has held it in 3 quarters since. The position peaked at $19.2K in Q4 2025. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

NewEdge Advisors held 13 shares of Ascendis Pharma A/S worth $3.47K as of Q2 2026.
NewEdge Advisors sold 30 Ascendis Pharma A/S shares in Q2 2026, an estimated $7.01K.
Ascendis Pharma A/S made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3816 holding.
NewEdge Advisors first reported a position in Ascendis Pharma A/S in Q4 2025 and has held it in 3 quarters since.
NewEdge Advisors's Ascendis Pharma A/S position peaked at $19.2K in Q4 2025.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.